Hematologic Malignancy
Mature T-Cell and NK-Cell Neoplasm
CI-CAN-00003263Explore in graph →
HematologicNon-malignant187 active trials13 approved drugs10 evidence items
- NCIt
- C27909
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003263Explore in graph →
Clinical trials
825 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07047885 | Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) | recruiting | Phase 1 | 38 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05160922 | Crizotinib Continuation Clinical Study | active not recruiting | Phase 4 | 27 | PfizerINDUSTRY | 5 | Mar 30, 2026 | clinicaltrials |
| NCT01846390 |
| Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma |
| completed |
| Phase 1 |
| 21 |
| Canadian Cancer Trials GroupNETWORK |
| 1 |
| Mar 27, 2026 |
| clinicaltrials |
| NCT07270861 | Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study | recruiting | — | 3,000 | Fudan UniversityOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04881838 | CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL | active not recruiting | Phase 3 | 172 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07477769 | Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)(NIPALYMPHO) | not yet recruiting | — | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT03590574 | Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma | terminated | Phase 1 / Phase 2 | 20 | Autolus LimitedINDUSTRY | 2 | Mar 16, 2026 | clinicaltrials |
| NCT07470996 | T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR(T-START-NR) | recruiting | — | 58 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02737046 | Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma | completed | Phase 2 | 15 | University of MiamiOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07457177 | Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL | not yet recruiting | Phase 2 | 40 | LIANG WANGOTHER | 0 | Mar 9, 2026 | clinicaltrials |
| NCT06698003 | A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 | recruiting | Phase 2 | 134 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor(KEAP) | available | — | — | Karyopharm Therapeutics IncINDUSTRY | 0 | Mar 2, 2026 | clinicaltrials |
| NCT06235281 | Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)(PLIGHT) | suspended | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04362007 | A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma | terminated | Phase 1 / Phase 2 | 8 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07414758 | Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy(T-START-M1) | recruiting | Phase 3 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06089941 | Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas(PTCL-SEQ) | active not recruiting | — | 45 | Centre Henri BecquerelOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04645199 | National Longitudinal Cohort of Hematological Diseases(NICHE) | recruiting | — | 2,300 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07018752 | A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas(PlaTform) | recruiting | Phase 1 / Phase 2 | 49 | The Lymphoma Academic Research OrganisationOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04848064 | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma | recruiting | Phase 1 | 12 | John ReneauOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05592015 | Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia | recruiting | Phase 2 | 30 | Jonathan BrammerOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05872854 | Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light(RW-HPN-MF-01) | completed | Phase 2 | 10 | Ellen Kim, MDOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06485219 | A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | active not recruiting | Phase 2 | 50 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05316116 | Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) | terminated | Early Phase 1 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07389616 | A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma | recruiting | Phase 2 / Phase 3 | 40 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05296304 | A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07385989 | Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 40 | WEI XUOTHER | 0 | Feb 4, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07180771 | A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. | not yet recruiting | Phase 2 | 44 | Boryung Pharmaceutical Co., LtdINDUSTRY | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07372352 | Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL | recruiting | Phase 2 | 26 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06069830 | PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma(ENKTL) | recruiting | N/A | 89 | Ruijin HospitalOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07362225 | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) | recruiting | — | 5,000 | MPN Research FoundationOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04747236 | Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL(PTCL) | recruiting | Phase 2 | 50 | University of VirginiaOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07353840 | T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR(T-START-CR) | recruiting | — | 160 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07347288 | SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma | not yet recruiting | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04220970 | Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry | recruiting | — | 150 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jan 14, 2026 | clinicaltrials |
| NCT07339527 | EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas | not yet recruiting | Phase 1 / Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT02264613 | ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 / Phase 2 | 142 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03210662 | Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04425070 | A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma(TOUCH) | terminated | Phase 1 / Phase 2 | 56 | Antengene CorporationINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07093710 | Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 101 | Sun Yat-sen UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT00177268 | Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research | recruiting | — | 200 | University of PittsburghOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05157581 | Extracorporeal Photopheresis in Sezary Syndrome(ECP) | recruiting | — | 20 | Oleg E. Akilov, MD, PhDOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06511895 | AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) | completed | Phase 2 | 57 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07253129 | Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)(T-START-PR) | recruiting | — | 88 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07283822 | Amping up With PemJAK | recruiting | Phase 2 | 53 | Seda S. ToluOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07279584 | Golidocitinib Combined With GemOx in RR PTCL | not yet recruiting | Phase 2 | 31 | Ruijin HospitalOTHER | 0 | Dec 12, 2025 | clinicaltrials |
| NCT07276698 | Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma | not yet recruiting | Phase 2 | 39 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07276737 | Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 37 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Dec 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Apr 1, 2026source: clinicaltrials